Reporting of cause-specific treatment effects in cancer clinical trials with competing risks: a systematic review.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Contemporary Clinical Trials

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cct.2012.05.013PMID 22664646
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statistical grand rounds: design and analysis of studies with binary- event composite endpoints: guidelines for anesthesia research.

  2011cited by this paper
• Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

  2011cited by this paper
• Population-based study of competing mortality in head and neck cancer.

  2011cited by this paper
• Sample size determination in clinical trials with multiple co‐primary binary endpoints

  2010cited by this paper
• Predictors of competing mortality in early breast cancer

  2010cited by this paper
• Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review

  2010cited by this paper
• Predictors of competing mortality in advanced head and neck cancer.

  2010cited by this paper
• Factors affecting power of tests for multiple binary outcomes

  2010cited by this paper
• Evaluating Health Outcomes in the Presence of Competing Risks: A Review of Statistical Methods and Clinical Applications

  2010cited by this paper
• Pitfalls of using composite primary end points in the presence of competing risks.

  2010cited by this paper
• Composite end points in randomized trials: there is no free lunch.

  2010cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Choice and interpretation of statistical tests used when competing risks are present.

  2008cited by this paper
• Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns.

  2007cited by this paper
• Challenge of multiple co‐primary endpoints: a new approach

  2007cited by this paper
• Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.

  2006cited by this paper
• Key issues in end point selection for heart failure trials: composite end points.

  2005cited by this paper
• Competing Causes of Death and Second Primary Tumors in Patients with Locoregionally Advanced Head and Neck Cancer Treated with Chemoradiotherapy

  2004cited by this paper
• A note on competing risks in survival data analysis

  2004cited by this paper
• Clinical trials--multiple treatments, multiple end points, and multiple lessons.

  2003cited by this paper
• Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues

  2003cited by this paper
• Composite outcomes in randomized trials: greater precision but with greater uncertainty?

  2003cited by this paper
• Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.

  2002cited by this paper
• Combined endpoints: can we use them?

  2002cited by this paper
• Clinical perspectives on the use of composite endpoints.

  1997cited by this paper
• Discussion: Some issues in the construction and use of clusters of outcome events

  1997cited by this paper
• Noncancer deaths in white adult cancer patients.

  1993cited by this paper
• Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens.

  1990cited by this paper

• Public access to protocols of contemporary cancer randomized clinical trials

  2021cites this paper
• Detecting a Survival Benefit to Dose Escalation.

  2019cites this paper
• Selection of Head and Neck Cancer Patients for Intensive Therapy.

  2019cites this paper
• Generalized Competing Event Models Can Reduce Cost and Duration of Cancer Clinical Trials.

  2018cites this paper
• Exploring multi-state modelling in an epidemiological and health economics context

  2018influential citation
• Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review

  2016cites this paper
• Competing events and costs of clinical trials: Analysis of a randomized trial in prostate cancer.

  2015cites this paper
• On lumping, splitting, and the nosology of clinical trial populations and end points.

  2014cites this paper
• Introducing prospective manuscript review to address publication bias.

  2014cites this paper
• Cause-specific effects of radiotherapy and lymphadenectomy in stage I-II endometrial cancer: a population-based study.

  2013cites this paper